Sellas Life Sciences Newsroom

We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate

Yahoo FinanceNov 16 20:28

Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 15 23:31 · Ratings

Promising Clinical Trials and Strong Financial Position Bolster Buy Rating for SELLAS Life Sciences Group

TipRanksNov 15 23:15 · Ratings

SELLAS Life Sciences Gr Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate

BenzingaNov 14 05:30

Sellas Life Sciences | 8-K: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SECNov 14 05:23

SELLAS Life Sciences 3Q Loss/Shr 10c >SLS

Dow JonesNov 14 05:22

Press Release: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Dow JonesNov 14 05:15

Express News | Sellas Life Sciences Q3 Operating Expenses USD 7.329 Million

BreakingsNov 14 05:15

Sellas Life Sciences | 10-Q: Q3 2024 Earnings Report

SECNov 14 05:08 · Announcements

Earnings Week Ahead: DIS, BABA, JD, CSCO, HD, OXY, SU, SHOP, AMAT, SPOT, and More

Seeking AlphaNov 10 21:01

SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses

BenzingaNov 5 23:02

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

GlobeNewswireNov 5 22:55

SELLAS Announces FDA Rare Pediatric Disease Designation for Its Leukemia Treatment

Seeking AlphaOct 15 21:34

Express News | Sellas Life Sciences Group Inc - Gps Phase 3 Regal Trial Interim Analysis Expected in Q4 2024

BreakingsOct 15 20:45

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

GlobeNewswireOct 15 20:45

Express News | Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia

BreakingsOct 15 20:45

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

GlobeNewswireOct 11 04:05

Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory

Yahoo FinanceSep 19 03:09

Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $4

Maxim Group analyst Jason McCarthy maintains $Sellas Life Sciences(SLS.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 23.1%

Futu NewsAug 16 00:32 · Ratings

Buy Rating Affirmed for SELLAS Life Sciences Amid Strong Financial Position and Promising Clinical Trials

TipRanksAug 15 23:45 · Ratings